Pfizer Inc. PFE,
and BioNTech SE BNTX,
He said Monday night that they have started a late-stage clinical trial for one of their COVID-19 vaccine candidates, which involves 30,000 people worldwide. The start of the trial “is a great step forward in our progress towards the provision of a potential vaccine to help combat the current COVID-19 pandemic, and we hope to generate additional data as the program progresses,” the statement said in a statement. Pfizer boss. Vaccine Research and Development Kathrin U. Jansen. Pfizer and BioNTech vaccine candidates have triggered T-cell responses in participants in addition to neutralizing antibody titers, and one of them is moving toward the larger trial. A T-cell response is believed to be critical for the human body to develop immunity to the new coronavirus, and candidates Pfizer-BioNTech and an AstraZeneca Plc AZN,
The candidates were the first vaccine candidates to show any response in T cells, a key component of the human body’s immune system. Several companies are competing to come up with a COVID-19 vaccine, with some believing that a vaccine might be available later this year or early 2021.
.
